Becton, Dickinson and Company (NYSE:BDX) Issues FY 2025 Earnings Guidance

Becton, Dickinson and Company (NYSE:BDX) issued an update on its FY 2025 earnings guidance on Thursday morning. The company provided earnings per share guidance of 14.250-14.600 for the period, compared to the consensus earnings per share estimate of 13.110. The company issued revenue guidance of $21.9 billion-$22.1 billion, compared to the consensus revenue estimate of $20.2 billion. Becton, Dickinson and Company also updated its FY25 guidance to $14.25-14.60 EPS.

Becton, Dickinson and Company Price Performance

Shares of NYSE BDX opened at $240.10 on Thursday. The company has a quick ratio of 1.36, a current ratio of 1.85 and a debt-to-equity ratio of 0.70. Becton, Dickinson and Company has a 52 week low of $218.75 and a 52 week high of $259.33. The business’s 50 day moving average price is $237.53 and its 200 day moving average price is $235.16. The firm has a market cap of $69.40 billion, a P/E ratio of 49.40, a P/E/G ratio of 1.76 and a beta of 0.43.

Becton, Dickinson and Company (NYSE:BDX) last issued its earnings results on Thursday, November 7th. The medical instruments supplier reported $3.81 EPS for the quarter, topping analysts’ consensus estimates of $3.77 by $0.04. Becton, Dickinson and Company had a return on equity of 14.49% and a net margin of 7.13%. The firm had revenue of $5.44 billion for the quarter, compared to the consensus estimate of $5.38 billion. During the same quarter in the prior year, the business earned $3.42 earnings per share. The company’s revenue was up 6.9% compared to the same quarter last year. On average, sell-side analysts expect that Becton, Dickinson and Company will post 13.11 earnings per share for the current year.

Becton, Dickinson and Company Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 31st. Investors of record on Monday, December 9th will be issued a $1.04 dividend. This is a boost from Becton, Dickinson and Company’s previous quarterly dividend of $0.95. This represents a $4.16 dividend on an annualized basis and a yield of 1.73%. Becton, Dickinson and Company’s dividend payout ratio is presently 78.19%.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on BDX shares. StockNews.com raised Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research note on Thursday, August 8th. Raymond James decreased their price objective on shares of Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating on the stock in a report on Friday, August 2nd. Evercore ISI boosted their target price on shares of Becton, Dickinson and Company from $286.00 to $290.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 1st. Citigroup raised shares of Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and raised their price target for the company from $255.00 to $275.00 in a research note on Tuesday, October 1st. Finally, Stifel Nicolaus increased their target price on Becton, Dickinson and Company from $270.00 to $280.00 and gave the company a “buy” rating in a report on Friday, July 26th. Nine research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $282.63.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.